Non-hormonal steroid modulators targeting NF-kB for muscular dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, such as Duchenne muscular dystrophy, lack effective solutions despite understanding the role of chronic NF-κB activation in muscle wasting, and existing therapies do not adequately address the underlying inflammatory and catabolic processes.
Innovation Solution
Development of novel non-hormonal steroid compounds and pharmaceutical compositions that modulate NF-κB activity by inhibiting IκB kinases (IKKs) to block the NF-κB pathway, thereby reducing muscle wasting symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for muscular dystrophies are used, then patients receive standard care, but the treatments do not effectively address chronic NF-κB activation and muscle wasting
Solution Approach 1:
The patent employs parameter changes by developing novel non-steroidal compound structures with specific molecular configurations (Formula I and Formula II) that target the NF-κB pathway. These compounds represent a fundamental change in the chemical parameter space compared to existing treatments, enabling selective inhibition of IκB kinases and subsequent NF-κB activation blockade, thereby addressing muscle wasting effectively
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate between the inflammatory stimulus and the NF-κB pathway. These compounds act as molecular mediators by binding to and inhibiting IκB kinases, preventing the phosphorylation and degradation of IκB proteins, thus blocking the signal transduction cascade that leads to NF-κB activation and muscle wasting
2Object-affected harmful factors
If existing therapies are used, then treatment is provided, but they do not adequately address underlying inflammatory and catabolic processes
Solution Approach 1:
The patent converts the harmful chronic NF-κB activation into a beneficial therapeutic target. By designing compounds that specifically inhibit IκB kinases, the invention transforms the pathological signaling pathway into a controllable target, allowing selective blockade of the harmful inflammatory and catabolic processes while preserving normal cellular functions
Solution Approach 2:
The patent extracts and isolates the specific molecular mechanism (IκB kinase activity) responsible for NF-κB activation from the complex inflammatory cascade. By targeting this specific enzymatic step with selective inhibitors, the therapy removes the harmful signaling component while leaving other physiological processes intact, thereby adequately addressing the underlying inflammatory and catabolic processes
Data Source
AI summary
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.